ENANTA PHARMACEUTICALS, INC Debt Securities, Available-for-sale, Unrealized Loss
ENANTA PHARMACEUTICALS, INC (ENTA) reported Debt Securities, Available-for-sale, Unrealized Loss of $575.00 thousand for the 12-month period ending 2018-09-30, per its 10-K filed 2018-11-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2018-11-29
- ENANTA PHARMACEUTICALS, INC debt securities, available-for-sale, unrealized loss for the quarter ending 2018-09-30 was -$247.00K.
- ENANTA PHARMACEUTICALS, INC debt securities, available-for-sale, unrealized loss for fiscal 2018 was $575.00K, a 205.85% increase from fiscal 2017.
- ENANTA PHARMACEUTICALS, INC debt securities, available-for-sale, unrealized loss for fiscal 2017 was $188.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|
| 2018-09-30 | -$247.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-29 | $575.00K 10-K · filed 2018-11-29 | |
| 2018-06-30 | $822.00K 10-Q · filed 2018-08-09 | ||
| 2017-09-30 | $188.00K 10-K · filed 2018-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |